Adamas Pharmaceuticals (NASDAQ:ADMS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Thursday.
According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “
A number of other equities research analysts have also issued reports on the stock. HC Wainwright set a $40.00 price objective on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a report on Monday, January 14th. Mizuho reissued a “hold” rating and issued a $11.00 target price on shares of Adamas Pharmaceuticals in a report on Friday, January 11th. Cowen set a $30.00 target price on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, November 1st. ValuEngine lowered shares of Adamas Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 2nd. Finally, Leerink Swann started coverage on shares of Adamas Pharmaceuticals in a report on Monday, November 12th. They issued an “outperform” rating and a $20.00 target price for the company. Two analysts have rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $31.25.
Shares of ADMS opened at $8.97 on Thursday. The company has a quick ratio of 8.74, a current ratio of 8.95 and a debt-to-equity ratio of 1.01. Adamas Pharmaceuticals has a 1 year low of $7.42 and a 1 year high of $36.63. The company has a market cap of $245.20 million, a price-to-earnings ratio of -2.26 and a beta of 1.41.
Hedge funds have recently bought and sold shares of the stock. First Mercantile Trust Co. grew its holdings in shares of Adamas Pharmaceuticals by 43.2% in the fourth quarter. First Mercantile Trust Co. now owns 5,765 shares of the specialty pharmaceutical company’s stock valued at $49,000 after purchasing an additional 1,740 shares in the last quarter. Pacer Advisors Inc. bought a new stake in Adamas Pharmaceuticals in the third quarter worth $104,000. Assenagon Asset Management S.A. bought a new stake in Adamas Pharmaceuticals in the fourth quarter worth $161,000. Tower Research Capital LLC TRC bought a new stake in Adamas Pharmaceuticals in the third quarter worth $162,000. Finally, SG Americas Securities LLC bought a new stake in Adamas Pharmaceuticals in the fourth quarter worth $210,000. 89.62% of the stock is owned by hedge funds and other institutional investors.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
Read More: Average Daily Trade Volume – ADTV
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.